List view / Grid view
Coronavirus or COVID-19 is currently the leading cause of mortality worldwide. With a patient database of 4,150,343 active cases (as of 28 June 2020), it is the most hit word on the internet today. Besides this catastrophe, the world has been facing a severe shortage of healthcare facilities, which has…
An outsourcing company has announced that Phase II, III and IV clinical trials of vaccines will continue at a growing number of sites, assessing the safety of each in light of COVID-19.
The FDA has approved Vascepa (icosapent ethyl) as a secondary therapy to reduce cardiovascular events in adults.
Pharmaceutical company, Sanofi, will eliminate jobs in France and Germany and end new in-house cardiology research programmes.
Researchers have suggested that benzodiazepines should be the first course of treatment for those with cardiovascular disease and anxiety...
A study has found that long term aspirin use increases patients' risk of major bleeding events by 43 percent, with 1 in 200 having a major bleed...
A study has shown that thousands of heart attacks and deaths caused by cardiovascular disease could be prevented through the use of statins...
A 3D bioprinting technique could, in the future, allow the creation of human tissue structures for the analysis of various diseases...
Portable biopharmaceutical drug manufacturers could be the future method of producing the drugs on demand for outbreaks of disease...
A new observational study has identified no benefit from prescribing statins to healthy pensioners aged over 75 to prevent heart disease...
Cardiac monitoring of high-risk breast cancer patients should be prioritised, after research revealed low rates of heart monitoring seen in the patients receiving trastuzumab.
A new online heart health calculator can predict the age of hearts and the risk to individuals of a serious cardiovascular event or death...
The results of a study presented at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that canakinumab significantly reduced the rate of gout by more than half, compared to placebo, regardless of baseline serum urate level.
Over the last decade, research has revealed more about the human gut microbiome—the environment within the gastrointestinal tract—where microbes, especially bacteria, reside.
10 January 2017 | By Niamh Marriott, Digital Editor
Novartis announced a collaboration and option agreement with Ionis Pharmaceuticals and its affiliate Akcea Therapeutics to license two novel treatments with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of lipoproteins known as Lp(a) and ApoCIII.
